Key result
BITA grafting remains justified over single ITA in younger patients without comorbidities despite null ART results.
Why the study?
Convincing evidence regarding the superiority of bilateral internal thoracic artery use in coronary artery bypass grafting remains lacking, and BITA grafts continue to be underutilized.
Does bilateral internal thoracic artery (BITA) grafting improve outcomes compared to single ITA grafting in patients undergoing CABG?
Does bilateral internal thoracic artery (BITA) grafting improve outcomes compared to single ITA grafting in patients undergoing CABG?
BITA grafting in CABG is recommended for younger patients without significant comorbidities, despite the ART trial not showing overall superiority at 10 years.
There is still lack of convincing evidence about the superiority of bilateral internal thoracic artery (BITA) use in coronary artery bypass grafting (CABG) and BITA grafts continue to be underutilized. Arterial Revascularization Trial (ART) did not demonstrate the superiority of BITA versus single ITA grafting after 10 years. We have reviewed the most recent literature, assessed the current status as well as indications of BITA grafting in the post-ART era. We believe that BITA grafting is not appropriate for all patients especially in light of the findings of ART. However, the use of BITA is justified in patients of younger age and those without comorbidities (poorly controlled diabetes, obesity, chronic obstructive pulmonary disease, previous mediastinal irradiation, long-term steroid use, elderly women). Further prospective randomized studies with long-term follow-up are needed to validate the benefits of BITA grafting.
No takes yet. Share an insight, caveat, or question.
Sef et al. (2020) conducted a review in Coronary artery disease requiring CABG. Bilateral internal thoracic artery (BITA) grafting vs. Single internal thoracic artery grafting was evaluated. Bilateral internal thoracic artery (BITA) grafting is justified in younger patients without comorbidities, despite the ART trial showing no 10-year superiority over single ITA grafting.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: